Search Results

Displaying Results 1-5 of 5 "'ABCL'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

Jul 23, 2026, 09:05 ET An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

financing.The broader AI-platform and computational-biology field includes Schrödinger (NASDAQ: SDGR), AbCellera Biologics (NASDAQ: ABCL), Relay Therapeutics (NASDAQ: RLAY), and Certara (NASDAQ: CERT), each pursuing its own model for turning software and data into durable

More news about: USA News Group

As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

Jul 15, 2026, 08:45 ET As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

appetite for the exact category MindWalk operates in: AI that designs biology rather than just analyzing it.AbCellera Biologics (Nasdaq: ABCL) shows how an AI-powered discovery platform can turn into clinical momentum. The Vancouver-based company hit a 52-week high in late June 2026 and has

More news about: Equity Insider

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data

Jul 01, 2026, 09:00 ET As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data

is moving in the same data-and-platform direction as other public life-sciences AI names, including Tempus AI (NASDAQ: TEM), AbCellera (NASDAQ: ABCL), Schrödinger (NASDAQ: SDGR), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for MindWalk.Patenting the Moat, Not

More news about: USA News Group

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 17, 2026, 07:00 ET Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

VANCOUVER, BC, June 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific

More news about: Jazz Pharmaceuticals plc

Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial

Oct 16, 2025, 05:00 ET Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial

investors who share a commitment to advancing transformative technologies. These investors have backed paradigm-shifting companies including AbCellera (ABCL), Atai Life Sciences (ATAI), New Amsterdam Pharma (NAMS), Compass Pathways (CMPS), Kriya Therapeutics, and F2G. This group combines deep domain expertise

More news about: Peptilogics

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.